vs
Apellis Pharmaceuticals, Inc.（APLS）与WABASH NATIONAL Corp（WNC）财务数据对比。点击上方公司名可切换其他公司
WABASH NATIONAL Corp的季度营收约是Apellis Pharmaceuticals, Inc.的1.5倍（$303.2M vs $199.9M），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -20.4%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-37.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -25.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
沃巴什国家公司是美国多元化工业制造企业，也是北美最大的半挂车与卡车车身生产商之一。公司主营干货厢式半挂车、冷藏厢式半挂车、平板半挂车、液罐半挂车、卡车车身及复合材料产品的设计与生产，自2022年起产品主要以沃巴什品牌进行销售。
APLS vs WNC — 直观对比
营收规模更大
WNC
是对方的1.5倍
$199.9M
营收增速更快
APLS
高出14.5%
-20.4%
自由现金流更多
APLS
多$23.0M
$-37.3M
两年增速更快
APLS
近两年复合增速
-25.8%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $303.2M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | 2.8% |
| 营业利润率 | -25.6% | 1.3% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | -20.4% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-1.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSWNC
| Q1 26 | — | $303.2M | ||
| Q4 25 | $199.9M | $321.5M | ||
| Q3 25 | $458.6M | $381.6M | ||
| Q2 25 | $178.5M | $458.8M | ||
| Q1 25 | $166.8M | $380.9M | ||
| Q4 24 | $212.5M | $416.8M | ||
| Q3 24 | $196.8M | $464.0M | ||
| Q2 24 | $199.7M | $550.6M |
净利润APLSWNC
| Q1 26 | — | — | ||
| Q4 25 | $-59.0M | $-49.9M | ||
| Q3 25 | $215.7M | $40.0M | ||
| Q2 25 | $-42.2M | $-9.6M | ||
| Q1 25 | $-92.2M | $230.9M | ||
| Q4 24 | $-36.4M | $-1.0M | ||
| Q3 24 | $-57.4M | $-330.2M | ||
| Q2 24 | $-37.7M | $29.0M |
毛利率APLSWNC
| Q1 26 | — | 2.8% | ||
| Q4 25 | — | -1.9% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | — | 9.0% | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | — | 12.1% | ||
| Q2 24 | — | 16.3% |
营业利润率APLSWNC
| Q1 26 | — | 1.3% | ||
| Q4 25 | -25.6% | -18.6% | ||
| Q3 25 | 48.7% | 15.1% | ||
| Q2 25 | -18.6% | -1.0% | ||
| Q1 25 | -50.0% | 82.6% | ||
| Q4 24 | -12.3% | 0.9% | ||
| Q3 24 | -24.0% | -93.3% | ||
| Q2 24 | -14.7% | 7.9% |
净利率APLSWNC
| Q1 26 | — | — | ||
| Q4 25 | -29.5% | -15.5% | ||
| Q3 25 | 47.0% | 10.5% | ||
| Q2 25 | -23.6% | -2.1% | ||
| Q1 25 | -55.3% | 60.6% | ||
| Q4 24 | -17.1% | -0.2% | ||
| Q3 24 | -29.2% | -71.2% | ||
| Q2 24 | -18.9% | 5.3% |
每股收益（稀释后）APLSWNC
| Q1 26 | — | $-1.11 | ||
| Q4 25 | $-0.40 | $-1.03 | ||
| Q3 25 | $1.67 | $0.97 | ||
| Q2 25 | $-0.33 | $-0.23 | ||
| Q1 25 | $-0.74 | $5.36 | ||
| Q4 24 | $-0.30 | $0.10 | ||
| Q3 24 | $-0.46 | $-7.53 | ||
| Q2 24 | $-0.30 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $43.4M |
| 总债务越低越好 | — | $498.0M |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSWNC
| Q1 26 | — | $43.4M | ||
| Q4 25 | $466.2M | $31.9M | ||
| Q3 25 | $479.2M | $91.7M | ||
| Q2 25 | $370.0M | $57.4M | ||
| Q1 25 | $358.4M | $81.0M | ||
| Q4 24 | $411.3M | $115.5M | ||
| Q3 24 | $396.9M | $81.8M | ||
| Q2 24 | $360.1M | $77.3M |
总债务APLSWNC
| Q1 26 | — | $498.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $425.0M | ||
| Q2 25 | — | $440.0M | ||
| Q1 25 | — | $420.0M | ||
| Q4 24 | — | $400.0M | ||
| Q3 24 | — | $400.0M | ||
| Q2 24 | — | $400.0M |
股东权益APLSWNC
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | $367.4M | ||
| Q3 25 | $401.2M | $418.7M | ||
| Q2 25 | $156.3M | $385.2M | ||
| Q1 25 | $164.2M | $403.8M | ||
| Q4 24 | $228.5M | $188.8M | ||
| Q3 24 | $237.1M | $200.5M | ||
| Q2 24 | $264.3M | $550.4M |
总资产APLSWNC
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $821.4M | $1.4B | ||
| Q1 25 | $807.3M | $1.4B | ||
| Q4 24 | $885.1M | $1.4B | ||
| Q3 24 | $901.9M | $1.5B | ||
| Q2 24 | $904.5M | $1.3B |
负债/权益比APLSWNC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.04× | ||
| Q4 24 | — | 2.12× | ||
| Q3 24 | — | 1.99× | ||
| Q2 24 | — | 0.73× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-33.7M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-37.3M |
| 自由现金流率自由现金流/营收 | -7.1% | -12.3% |
| 资本支出强度资本支出/营收 | 0.1% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-41.4M |
8季度趋势，按日历期对齐
经营现金流APLSWNC
| Q1 26 | — | $-33.7M | ||
| Q4 25 | $-14.2M | $-57.4M | ||
| Q3 25 | $108.5M | $85.2M | ||
| Q2 25 | $4.4M | $-15.8M | ||
| Q1 25 | $-53.4M | $-272.0K | ||
| Q4 24 | $19.4M | $80.9M | ||
| Q3 24 | $34.1M | $42.8M | ||
| Q2 24 | $-8.3M | $11.0M |
自由现金流APLSWNC
| Q1 26 | — | $-37.3M | ||
| Q4 25 | $-14.3M | $-61.9M | ||
| Q3 25 | $108.3M | $79.9M | ||
| Q2 25 | $4.4M | $-22.1M | ||
| Q1 25 | $-53.4M | $-9.0M | ||
| Q4 24 | $19.3M | $59.5M | ||
| Q3 24 | — | $28.2M | ||
| Q2 24 | $-8.4M | $-6.1M |
自由现金流率APLSWNC
| Q1 26 | — | -12.3% | ||
| Q4 25 | -7.1% | -19.3% | ||
| Q3 25 | 23.6% | 20.9% | ||
| Q2 25 | 2.5% | -4.8% | ||
| Q1 25 | -32.0% | -2.4% | ||
| Q4 24 | 9.1% | 14.3% | ||
| Q3 24 | — | 6.1% | ||
| Q2 24 | -4.2% | -1.1% |
资本支出强度APLSWNC
| Q1 26 | — | 1.1% | ||
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 1.4% | ||
| Q1 25 | 0.0% | 2.3% | ||
| Q4 24 | 0.0% | 5.1% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 3.1% |
现金转化率APLSWNC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 2.13× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WNC
暂无分部数据
